Optimizing Early Stage Drug Development and Best Practices in Clinical Trial Supply Management to be Presented by Catalent Experts at Biopharma Asia in Singapore

Share Article

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health products and global clinical supply services, today announced that Mr. Paul Cao, General Manager, Clinical Trial Supply, China, and Mr. Julien Meissonnier, Vice President, Science and Technology, will be presenting at the upcoming BioPharma Asia Conference, to be held at the Suntec Singapore International Exhibition & Convention Centre, Singapore, on March 22nd – 24th, 2016.

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health products and global clinical supply services, today announced that Mr. Paul Cao, General Manager, Clinical Trial Supply, China, and Mr. Julien Meissonnier, Vice President, Science and Technology, will be presenting at the upcoming BioPharma Asia Conference, to be held at the Suntec Singapore International Exhibition & Convention Centre, Singapore, on March 22nd – 24th, 2016.

Mr. Cao’s presentation, on Wednesday March 23rd, at 12:40 p.m., is entitled “Best Practice and Considerations for Running Successful Clinical Trials in and from Asia,” and will discuss current trends and challenges facing companies running clinical trials in this market, and strategies to overcome these. A case study demonstrating successful planning through combining clinical supply management and a patient- and site-centric supply network will be presented, while Mr. Cao will also discuss approaches for Asian innovators looking to manage clinical trials in the US and Europe.

Later that day at 2:00 p.m., Mr. Meissonnier is to present “Accelerating Oral Drug Development Through Systematic Early Technology Selection.” He will discuss how accurate early stage prediction of compounds’ physicochemical and biopharmaceutical properties can be beneficial in the selection of suitable technologies that optimize bioavailability, safety, and stability of any new chemical entity. The presentation will also demonstrate how working with development partners with expertise in preformulation and formulation development can facilitate successful and streamlined design of pharmacokinetic and efficacy/toxicity studies, leading to pharmacologically effective and developable candidates entering the clinic, and ultimately the market, faster.

Prior to joining Catalent, Mr. Cao was most recently the General Manager for Fisher Clinical Service (Beijing, China). An industry veteran, who is experienced with GMP and FDA certification in China, he has an extensive background in secondary packaging and cold chain distribution. Prior to Fisher he worked for Zuellig Pharma and has extensive experience in drug distribution. Mr. Cao has a Bachelor of Science Degree in Industrial Electrical Automation from Beijing University of Science and Technology and also holds an MBA from Vlerick Leuven Ghent Management School, K. U. Leuven, Belgium. Additionally, he has a Bachelor’s degree in Computer Science & Artificial Intelligence from K. U. Leuven, Belgium.

As Vice President, Science and Technology at Catalent, Julien Meissonnier leads the company's scientific, technology, and product development. Previously, he led Catalent's European R.P. Scherer softgel R&D teams, focussed on early stage screening activities, product development, scale-up and technology transfer, directing clinical supplies, and supporting product launches. Mr. Meissonnier has 17 years of experience in pharmaceutical development. He earned his Engineering degree in Physico-Chemistry from the ENSI in Caen, France. He is also a member of the Board of the Catalent Applied Drug Delivery Institute.

For more information on the 2016 BioPharma Asia Conference and Exhibition, visit: http://www.terrapinn.com/exhibition/bio-asia/index.stm and to arrange a meeting with attending Catalent executives at the event, contact Richard Kerns at NEPR- richard(at)nepr(dot)eu.

About Catalent

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and global clinical supply services. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Halling

Richard Kerns
Northern Exposure PR
+44 7974 579202
Email >
Visit website